Other NIH Programs for Translational Neuroscience that Support Biologics

Funding for Assay Development and Screening

IGNITE: Assay Development and Neurotherapeutic Agent Identification

  • Support: 3-year R61/R33 to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential neurotherapeutic agents
  • Participating Institutes: NINDS, NCCIH
  • To apply: PAR-21-124

 

Funding for Preclinical Proof-of-Concept

Drug Discovery for Nervous System Disorders

IGNITE: Neurotherapeutic Agent Characterization and In vivo Efficacy Studies

  • Support: 3-year R61/R33 to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development
  • Participating Institute: NINDS
  • To apply: PAR-21-122

 

Funding for Translational Model Development

IGNITE: Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery

  • Support: 3- year R61/R33 to support development and validation of animal models and ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder
  • Participating Institute: NINDS
  • To apply: PAR-21-123

 

Funding for Preclinical/Clinical Development

National Cooperative Drug Discovery/Development Groups (NCDDG)

Investigational New Drug (IND)-enabling Development of Medications to Treat Alcohol Use disorder and Alcohol-related disorders (STTR)

  • Support: Up to 2 years for Phase I and up to 3 years for Phase II may be requested. Budgets up to $1.0M total costs per year for Phase I and up to $1.5 total costs per year for Phase II may be requested.
  • Participating Institute: NIAAA
  • To apply: PAR-18-580 (UT2 - Clinical Trial Optional)

Investigational New Drug (IND)-enabling Development of Medications to Treat Alcohol Use disorder and Alcohol-related disorders (SBIR)

  • Support: Up to 2 years for Phase I and up to 3 years for Phase II may be requested. Budgets up to $1.0M total costs per year for Phase I and up to $1.5 total costs per year for Phase II may be requested.
  • Participating Institute: NIAAA
  • To apply: PAR-18-578 (U44 - Clinical Trial Optional)

Strategic Alliances for Medications Development to Treat Substance-Use Disorders

  • Support: Up to 3 years of funding, includes discovery, development, and clinical trials. $3M per year with expectation of matching funds
  • Participating Institute: NIDA
  • To apply: PAR-19-318 (R01)

Grand Opportunities in Medications Development for Substance-Use Disorders

  • Support: Up to 3 years of funding, milestone-driven, up to $5M per year
  • Participating Institute: NIDA
  • To apply: PAR-19-327 (U01)

Alzheimer's Drug-Development Program

  • Support: Up to 5 years of funding, milestone-driven, up to $1M per year
  • Participating Institute: NIA
  • To apply: PAR-18-820 (U01)

 

Services

Services for Pharmacology

Epilepsy Therapy Screening Program (ETSP)

  • Support: Screens compounds in animal seizure models
  • To apply: Contact Brian Klein, Ph.D.

Addiction Treatment Discovery Program (ATDP)

  • Support: Screens compounds in animal models of addiction
  • To apply: Contact David White, Ph.D., (301) 443-8889

Services for Toxicology

Bridging Interventional Development Gaps (BrIDGs)

NIDA Toxicology Program

  • Support: Provides IND-directed toxicology services for substance abuse indications.
  • To apply: Contact Nathan M. Appel, Ph.D., (301) 443-8475

Regulatory Affairs Assistance for Medications Development

  • Support: Provides consultation and advice on regulatory requirements
  • Participating Institute: NIDA
  • To apply: Contact Robert Walsh, R.A.C.

BPN-Biologics Staff

Program Director
Dr. Mario Skiadopoulos 

Health Program Specialists
Ms. Elena Barnaeva
Ms. Shruthi Thomas

 

Project Manager

Ms. Sonia Gales

Operations Coordinator
Ms. Natasha Davis

CONTACT US

Was this page helpful?
Form Approved OMB# 0925-0648 Exp. Date 06/2024